ABBV 552
Alternative Names: ABBV-552; SDI-118Latest Information Update: 28 Feb 2025
At a glance
- Originator UCB Biopharma
- Developer AbbVie
- Class Antidementias; Nootropics; Small molecules
- Mechanism of Action SV2A protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
- No development reported Cognition disorders
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Cognition-disorders(In the elderly) in Germany (PO, Capsule)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Cognition-disorders(In the elderly) in United Kingdom (PO, Capsule)
- 28 Oct 2024 No recent reports of development identified for phase-I development in Cognition-disorders(In adults) in United Kingdom (PO, Capsule)